Broadcom named strategic vendor for Walmart virtualization solutions
Samarth Kulkarni, CEO of CRISPR Therapeutics AG (NASDAQ:CRSP), recently executed several stock transactions, according to a Form 4 filing with the Securities and Exchange Commission. On March 11 and March 12, Kulkarni sold a total of 14,435 common shares at prices ranging from $42.42 to $43.32 per share, amounting to a total sale value of $616,348. The stock, currently trading at $43.49, has shown significant volatility according to InvestingPro data.
Additionally, Kulkarni acquired 28,250 common shares through the vesting of restricted stock units (RSUs) on March 10 and March 11. These transactions were part of the company’s RSU Settlement Policy, which mandates sales to cover tax withholding obligations, rather than discretionary trades. Following these transactions, Kulkarni holds 185,428 shares directly in the $3.74 billion market cap company. InvestingPro analysis shows CRISPR maintains strong liquidity with a current ratio of 22.07, and its overall financial health is rated as FAIR. Discover more insights and 8 additional ProTips for CRISPR Therapeutics in the comprehensive Pro Research Report.
In other recent news, CRISPR Therapeutics has seen varied analyst actions and updates on its pipeline. Citi analysts have lowered their price target for CRISPR Therapeutics to $82 while maintaining a Buy rating, citing progress with Casgevy, which has activated over 50 treatment centers globally. Meanwhile, Evercore ISI upgraded CRISPR Therapeutics’ stock to Outperform and increased their price target to $99, driven by optimism about upcoming catalysts and the company’s strong cash position of $1.9 billion. Stifel analysts, however, reduced their price target to $49, maintaining a Hold rating due to concerns about the market uptake of Casgevy. TD Cowen also adjusted their stance, upgrading the stock from Sell to Hold with a steady price target of $35, noting reduced downside risk.
CRISPR Therapeutics’ pipeline developments are drawing attention, with significant updates expected in 2025 for various programs, including CTX112 in B-cell malignancies and systemic lupus erythematosus, and in vivo programs CTX320 and CTX310. Evercore ISI highlighted the potential impact of these programs on atherosclerotic cardiovascular disease, with data anticipated in the second quarter of 2025. Despite differing views, analysts are closely monitoring CRISPR Therapeutics’ strategic moves, particularly concerning the launch of Casgevy and advancements in its gene-editing pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.